November 17, 2021
Life Sciences
  • The FDA’s committee of outside experts is not planning to meet to discuss the data on Pfizer’s request for the agency to authorize COVID-19 boosters for all adults. The panel twice voted to reject boosters for the young and healthy who don’t face high exposure risks. The FDA is aiming to authorize booster doses as early as Thursday and the CDC could greenlight boosters on Friday, when an independent committee of vaccine experts is meeting to discuss data on the booster dose’s efficacy and safety. (Articles here, here, here, and here)